2023 American Society of Hematology (ASH) Annual Meeting & Exposition

Stanford is honored to have 26 presenters at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition. The conference will occur December 9-12 in person in San Diego, CA, and online. The Stanford Cancer Institute will be present at the meeting and will host our first-ever conference booth. Visit us during the meeting at booth #3436 to connect and grab some Stanford Cancer Institute-branded swag. 

Catherine Aftandilian, MD

Myeloid Malignancies: Real-world Treatment Patterns and Outcomes

Sunday, December 10

Stefan K. Alig, MD

Genomic, Transcriptional, and Immunological Validation of Distinct Molecular Subtypes of Classic Hodgkin Lymphoma Through Tissue-based and Noninvasive Methods

Saturday, December 9

 

Marc-Andrea Baertsch, MD

Spatial Dissection of the Bone Marrow Microenvironment in Multiple Myeloma by High Dimensional Multiplex Tissue Imaging

Saturday, December 9

Alice Bertaina, MD, PhD

Stem Cell Transplantation for ALL: You’ve Always Got a Donor, Why Not Always Use It?

Saturday, December 9

Cailin T. Collins, MD, PhD

Engineering Sequential Mutations Into Human HSPCs Yields an Aggressive Myeloid Malignancy Allowing for Interrogation of Preleukemic Transformation

Monday, December 11

Jordan Goldstein, MD, MSc

Optimizing Circulating Tumor DNA Limits of Detection for DLBCL During First Line Therapy

Saturday, December 9

Mark P. Hamilton, MD

CAR19 Therapy Drives Expansion of Clonal Hematopoiesis and Associated Cytopenias

Saturday, December 9

Daiki Karigane, MD, PhD

Intra-leukemic IFNγ Signaling Mediates Cell Cycle Suppression and Chemoresistance in AML

Sunday, December 10

Y. Lucy Liu, MD, PhD

Novel Mouse Model That Recapitulates the Hematologic Phenotype of Diamond Blackfan Anema

Monday, December 11

Jurik A. Mutter, PhD

Inferred Gene Expression by Cell-free DNA Profiling Allows Noninvasive Lymphoma Classification

Saturday, December 9

Matthew Schwede, MD

The Shifting Prognosis of FLT3 Mutations in Acute Myeloid Leukemia in the Era of Targeted Therapy: A Real-world Study Using Large-scale Electronic Health Record Data

Monday, December 11

Riya Sinha, MS

Harnessing Artificial Intelligence for Risk Stratification in Acute Myeloid Leukemia (AML): Evaluating the Utility of Longitudinal Electronic Health Record (EHR) Data Via Graph Neural Networks

Monday, December 11

Katja G. Weinacht, MD, PhD

Accelerating Immune Reconstitution in HSCT Patients Through iPSC-derived Thymic Epithelial Cells

Sunday, December 10

Rajni Agarwal, MD

Radiation and Busulfan-free Hematopoietic Stem Cell Transplantation Using Briquilimab (JSP191) Anti-CD117 Antibody-conditioning, Transient Immunosuppression and TCRI+-I2+ T-cell/CD19+ B-cell Depleted Haploidentical Grafts in Patients With Fanconi Anemia

Saturday, December 9

Ash A. Alizadeh, MD, PhD

Circulating Tumor DNA Dynamics as Early Outcome Predictors for Lisocabtagene Maraleucel as Second-Line Therapy for Large B-Cell Lymphoma From the Phase 3 TRANSFORM Study

Saturday, December 9

Glaivy Batsuli, MD

Reimagining Outcomes in Hemophilia: Improving Efficacy and Reducing Treatment Burden With High-sustained Factor and Non-factor Replacement Therapies

Friday, December 8

Ami S. Bhatt, MD

Microbiota and the Development of Hematological Malignancies

Sunday, December 10

Tamara J. Dunn, MD

Diversity, Equity, and Inclusion Considerations & Recruitment

Friday, December 8

 

Tanja A. Gruber, MD, PhD

Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Biomarkers and Therapeutics
Saturday, December 9 

Outcome of Infants Treated on Total Therapy for Infants With Acute Lymphoblastic Leukemia I: Results From a Non-Randomized Multi-center Study
Monday, December 11

Kendra K. Jackson

BCOR Loss Confers Increased Stemness and Partially Rescues RUNX1-Deficient Phenotypes in Human Hematopoietic Stem and Progenitor Cells

Monday, December 11

Thomas Koehnke, MD

Gene Correction of DNMT3A:R882H in Primary Human AML Demonstrates That This Mutation is Not Required for Disease Maintenance, but Is Associated With Increased Leukemia Stem Cell Frequency

Sunday, December 10

Ravindra Majeti, MD, PhD

Synthetic Lethal Metabolic Dependencies in IDH1-mutant Acute Myeloid Leukemia

Friday, December 8

Joseph Schroers-Martin, MD

Post Transplant Lymphoproliferative Disorder and Its Ecosystem
Friday, December 8 

Longitudinal Noninvasive Surveillance & Fragmentomic Characterization of Follicular Lymphoma
Sunday, December 10

Surbhi Sidana, MD

T-cell Radiation Therapy for Multiple Myeloma
Sunday, December 10 

Real World Outcomes With Idecabtagene Vicleucel (Ide-Cel) CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma
Monday, December 11 

Managing Side Effects: Guidance for Use of Immunotherapies in Multiple Myeloma
Monday, December 11

Melody Smith, MD, MS

Cellular Immunotherapies: Basic and Translational: Overcoming Challenges in CAR-T Therapies Through Biological Insights
Saturday, December 9 

Cellular Immunotherapies: Early Phase and Investigational Therapies: CAR-T Cell Therapies for Multiple Myeloma and B Cell Lymphomas
Monday, December 11

Ellen Zhang, MD

Hereditary Hemorrhagic Telangiectasia May Be the Most Clinically Significant and Morbid Inherited Bleeding Disorder of Women

Saturday, December 9